Zevallos says that while HPV-positive oropharyngeal SCC has a positive outcome for patients, smoking status should be taken into account for these patients when making a decision to deintensify therapy.
Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses the inequality of HPV-positive oropharyngeal squamous cell carcinoma (SCC). Zevallos says that while HPV-positive oropharyngeal SCC has a positive outcome for patients, smoking status should be taken into account for these patients when making a decision to deintensify therapy. He adds that medical professionals should not set an "arbitrary" bar for how much a patient smokes as a "dangerous amount," but instead turn to molecular testing.
FDA Grants Fast Track Designation to MVR-T3011 in HNSCC
March 20th 2024The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More